Evolent Health, Inc. (EVH) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Evolent Health, Inc. operates as a holding company with its principal operating subsidiary, Evolent Health LLC, providing specialty care management and total cost of care management solutions to health plans and risk-bearing entities. The company operates in a single reportable segment.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $496.2 million | $483.6 million |
| Operating Loss | $(10.6) million | $(1.6) million |
| Net Loss (Common Shareholders) | $(26.6) million | $(72.3) million |
| Diluted EPS | $(0.24) | $(0.63) |
| Operating Cash Flow | $(1.0) million | $4.6 million |
| Cash & Restricted Cash | $168.7 million | $277.8 million |
| Total Debt (Principal) | $569.3 million (Notes) + $364.7 million (Credit Facilities) | N/A |
| Medical Expense Ratio (MER) | 93.3% | 68.0% |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 2.6% year-over-year, driven by an $83 million increase from a new Performance Suite contract go-live. This was partially offset by a $58 million reduction due to the December 2025 disposition of Evolent Care Partners (ECP) and a $17 million decline in Medicare memberships.
- Profitability: Operating loss widened to $10.6 million from $1.6 million. Net loss improved significantly to $26.6 million from $72.3 million, primarily due to the absence of a $52.5 million "Loss on option exercise" recorded in Q1 2025 related to a joint venture purchase.
- Cost Structure: Cost of revenue increased 8.2% to $412.5 million. The Medical Expense Ratio (MER) rose to 93.3% from 68.0%, attributed to the maturation profile of the new Performance Suite contract and higher claims costs.
- Debt Profile: Interest expense increased to $16.9 million from $10.4 million due to new borrowings under the First Lien Credit Agreement and the exchange of Series A Preferred Stock for a Second Lien Term Loan Facility in late 2025.
Guidance, Outlook, and Risks
- Regulatory Impact: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, which alters Medicaid and Medicare requirements. This may lead to reduced membership and higher member acuity, potentially impacting future revenue.
- Industry Trends: Medical claims costs in the Performance Suite continue to grow faster than historical norms due to higher disease prevalence and cost per active patient. Customers are reporting membership declines in Medicaid and Health Exchanges.
- Liquidity: Management believes current cash and cash equivalents ($142.0 million unrestricted) are sufficient to meet working capital and capital expenditure requirements for at least the next 12 months.
- Legal Proceedings: The company is cooperating with a Department of Justice Civil Investigative Demand (CID) regarding a former customer's Medicare Advantage billing practices. No material loss can currently be estimated.
Investor Verification Checklist
- Medical Expense Ratio (MER) Sustainability: Verify if the 93.3% MER is a temporary anomaly due to the new contract go-live or a structural shift in cost dynamics.
- Membership Trends: Monitor the impact of the OBBBA on Medicaid and Health Exchange membership numbers in upcoming quarters.
- Debt Service Capacity: Assess the ability to service the increased interest expense ($16.9M/quarter) given the current operating loss.
- Regulatory Investigation: Track the status and potential financial impact of the DOJ CID regarding the former customer.
- Contract Concentration: Note that Molina Healthcare, Inc. represented 24.0% of revenue in Q1 2026; monitor the stability of this key partnership.